SOSTOS
A randomized, open label, multi-center, active-comparator study to assess the efficacy, safety and tolerability of ofatumumab 20mg sc monthly versus continued current therapy in relapsing-remitting multiple sclerosis after elevation of serum neurofilament light levels (SOSTOS)
- Sex: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase IV
- Conditions Being Studied: Brain and Nervous System
Study Purpose
MS is a long-term illness where the body’s immune system attacks and damages the protective covering (called myelin) around the nerves in the central nervous system. People with relapsing MS (relapsing-remitting MS or secondary progressive MS with relapses) will have repeated attacks, or “relapses.” The purpose of the study is to find out if patients who have not had a relapse in the past year would benefit from switching to ofatumumab compared to continuing their current MS treatment. This study will also look at serum neurofilament light (NfL). NfL is a biomarker that may be an indicator of damage in a variety of neurological disorders.
Who Can Participate
Age: 18-45 years old
- UH IRB: SITE00001945 / STUDY20230207
- StudyID: 2022-0964
- ClinicalTrials.gov: NCT05090371
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422